Home
You have an old version of Adobe's Flash Player. Get the latest Flash player.
HomeAbout UsGalleryNewsOrganizational UnitsProductsChartContact Us

Lozar


Category:

Antihypertensive , angiotensin II receptor antagonist.

 

Indications:

Lozar is indicated for the treatment of hypertension, hypertension with left ventricular hypertrophy, diabetic nephropathy

 

Dosage and Administration:

Hypertension

Initial: 50mg qd
Max: 100mg qd

Hypertension with Left Ventricular Hypertrophy

Reduction in Risk of Stroke:
Initial: 50mg qd
Titrate: Add hydrochlorothiazide (HCTZ) 12.5mg qd and/or increase losartan to 100mg qd, followed by an increase in HCTZ to 25mg qd based on BP response.

Diabetic Nephropathy

Elevated SrCr/Proteinuria (Urinary Albumin to Creatinine Ratio ≥300mg/g) in Patients with Type 2 Diabetes and a History of HTN:
Initial: 50mg qd
Titrate: Increase to 100mg qd based on BP response

Usage in pregnancy and lactation:

Pregnancy Categories C (first trimester) and D (second and third trimesters).

Not for use in nursing.

 

Contraindications:

Hypersensitivity to any component of the medication, coadministration with aliskiren in patients with diabetes.

Warning and precautions:

Symptomatic hypotension may occur in patients with an activated RAS (eg, volume- or salt-depleted patients); correct volume or salt depletion prior to administration of therapy.

 Patients whose renal function may depend in part on the activity of the RAS may be at risk of developing acute renal failure; monitor renal function periodically.

Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on losartan.

Monitor serum K+ periodically and treat appropriately; dosage reduction or discontinuation of losartan may be required.

 

Drug Interactions:

Concomitant use of potassium – sparing diuretics (e.g.,spironolactone , triamterene, amiloride) , potassium supplements , or salt substitutes containing potassium may lead to increases in serum potassium.

Increases in serum lithium concentrations and lithium toxicity reported; monitor serum lithium levels during concomitant use. 

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration with  NSAIDs, including selective COX-2 inhibitors, may result in deterioration in renal function, including possible acute renal failure.

Antihypertensive effect may be attenuated by NSAIDs, including selective COX-2 inhibitors.

Dual blockade of the RAS is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure); avoid combined use of RAS inhibitors. Closely monitor BP, renal function, and electrolytes with concomitant agents that affect the RAS.

Avoid with aliskiren in patients with renal impairment (GFR <60mL/min). 

 

Adverse Reactions:

Dizziness, URI, nasal congestion, back pain.

Storage:

Store below 30° C.

Protect from light.

All rights reserved by Razak Laboratory Co.